Abstract
This narrative review describes the background to the introduction of the UK Psychoactive Substances Act 2016, and developments since the Home Office review of the Act in 2018. It discusses the challenges when measuring illicit drug proliferation, and triangulates the impact of the Act by using data from multiple public sources. It looks at both the direct impacts of the Act, and indirect impacts on other forms of drug use, and identifies the discrepancy between politically expedient legislation and real-world harm reduction.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
